Biocon Limited has appointed Shreehas Tambe as its Chief Executive Officer and Managing Director, effective April 1, 2026.
As the first CEO of the integrated Biocon, Tambe will lead the combined biosimilars and generics platform, enhancing the company’s scale and competitiveness in global markets.
The company also announced the appointment of Kedar Upadhye as Chief Financial Officer.